Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury
NCT05728840, Not applicable, Recruiting, Mindmaze SA
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury | ClinicalTrials.gov |
| NCT number | NCT05728840 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 135 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Mindmaze SA | ClinicalTrials.gov |
| Conditions | Stroke, Attention Disorder | ClinicalTrials.gov |
| Interventions | Immersive virtual reality gamified cognitive activities, Double neuropsychological standard activities | ClinicalTrials.gov |
| First posted | 2023-02-15 | ClinicalTrials.gov |
| Last updated | 2026-02-17 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline in Test of Attentional Performance (TAP) | Before the intervention (baseline) and after 20 days of training (end of intervention), within 7 weeks from first day of training | Main deficit of Attention | ClinicalTrials.gov |
| Secondary | Test of Attentional Performance (TAP) | Before the intervention (baseline), after 10 days of training (mid-training), 3-4 and 6-12 months after the end of intervention | Main deficit of Attention | ClinicalTrials.gov |
| Secondary | Test of Attentional Performance (TAP) | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | Other deficits of attention | ClinicalTrials.gov |
| Secondary | Wechsler Memory Scale (WMS-III) | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Brief Visuospatial Memory Test (BVMT) | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Stroop test | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Rating Scale of Attentional Behaviour (RSAB) | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Catherine Bergego Scale (CBS) | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Stroke impact Scale (SIS) | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Far space attention: Hemineglect far space Immersive VR-based task | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Response to saliency: Immersive VR-based free-viewing exploration (FVE-VR) task | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Credibility/Expectancy Questionnaire (CEQ) | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Fatigue: Penner questionnaire | Before the intervention (baseline), after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Immersive VR-based attentional performance task | Before the intervention (baseline), after each cycle of 5 days of training, after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | Defense Automated Neurobehavioral Assessment (DANA) | Before the intervention (baseline), after each cycle of 5 days of training, after 20 days of training (end of intervention), 3-4 and 6-12 months after the end of intervention | ClinicalTrials.gov | |
| Secondary | User Engagement Scale (UES) | After 20 days of training (end of intervention) | ClinicalTrials.gov | |
| Secondary | NASA task load index (NASA-TLX) | After 20 days of training (end of intervention) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)